<DOC>
	<DOCNO>NCT00851929</DOCNO>
	<brief_summary>Hypothesis : Ambrisentan ( Letairis ® ) safe effective treat pulmonary hypertension patient Sarcoidosis</brief_summary>
	<brief_title>Ambrisentan ( Letairis ) Sarcoidosis Associated Pulmonary Hypertension</brief_title>
	<detailed_description>Primary Endpoint : Change 6 minute walk distance . Secondary Endpoints : - Safety - Oxygen saturation rest exercise - Hospitalization - Mortality - WHO functional class - Quality life measure - Short-form 36 - Sarcoidosis Health Questionnaire - Dyspnea measure - Borg Dyspnea Index - St. George Respiratory Questionnaire - Sarcoidosis activity measure - STAI sarcoidosis instrument ( 33 ) - Prednisone dose - Pulmonary function - Forced vital capacity ( FVC ) - Diffusion ( DLCO ) - Endothelin-1 level - Bronchoalveolar lavage - Plasma - B-type natruetic peptide - Inflammatory fibrotic mediator ( IL-2 , IL-6 , IL-12 , IL-18 , IL-23 , TNF-α ) BALF - Compliance treatment - Time clinical worsening ( define initiation ambrisentan treatment first occurrence death , lung transplantation , hospitalization pulmonary arterial hypertension , arterial septostomy , change chronic prostanoid sildenafil treatment due protocol define worsen criterion study withdrawal due additional clinically approve PAH therapeutic agent )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<criteria>Biopsy proven sarcoidosis Mean pulmonary artery pressure &gt; 25 mmHg rest great 30 mmHg exercise right heart catheterization within 1 year prior entry study Pulmonary capillary wedge pressure ≤ 15 mmHg PVR value &gt; 3.0 Woods unit Forced vital capacity ( FVC ) &gt; 40 % WHO functional class II III Stable sarcoidosis treatment regimen three month prior entry study 6 minute walk distance 150450 meter Stable dose antihypertensive medication On medication treat PAH ( sildenafil , tadalafil , vardenafil , treprostinil , epoprostenol , iloprost , bosentan , sitaxsentan ) within one month prior enrollment duration study Nonpregnant females Exercise limitation relate noncardiopulmonary reason ( e.g . arthritis ) Severe systemic hypertension &gt; 170/95 Patients congestive heart failure ( left ventricular dysfunction ) primary right ventricular dysfunction Anticipation investigator escalation sarcoidosis treatment course study Pulmonary hypertension relate etiology sarcoidosis ( i.e . HIV , scleroderma , etc . ) Use within 1 month endothelin receptor antagonist ( bosentan , sitaxsentan ) . WHO functional class IV status Patients significant leave ventricular dysfunction Significant liver dysfunction due sarcoidosis . Patients severe organ disease felt investigator impact survival course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>sarcoidosis</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>dyspnea</keyword>
	<keyword>sarcoidosis associate pulmonary hypertension</keyword>
</DOC>